Ravi Madan

30PUBLICATIONS
84CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyPsychophysiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Jul 24, 2026
Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancer.

|Apr 11, 2026
EMBARK in biochemically recurrent prostate cancer: a journey for some but not most.

Melissa L Abel, Fatima Karzai, Ravi A Madan

|Mar 25, 2026
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.

Chennan Li, Ravi A Madan, Min-Jung Lee

|Feb 11, 2026
Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel.

Rana R McKay, Benjamin L Maughan, Alicia K Morgans

|Oct 23, 2025
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.

David J Einstein, Melissa L Abel, Jeanny B Aragon-Ching

|Oct 14, 2025
Therapeutic targeting of prostate-specific membrane antigen could limit its potential as benchmark imaging.

Melissa L Abel, Adam Sharp, Edwin M Posadas

Pageof 5

Frequent Collaborators

12 joint publications

Fatima Karzai

12 joint publications

James L Gulley

9 joint publications

Jeffrey Schlom

8 joint publications

Marijo Bilusic